Demographics and therapy
| Total n | 143 |
| Male:female | 77:66 |
| Age (range) | 11* (5.2–17.5) years |
| Ethnic group | Mixed ancestry 138 Caucasian 4 African 1 |
| Asthma score† | 1.43* (0.14–4.14) |
| ICS and device | BUD Hfa MDI and spacer 128 BUD Hfa MDI 11 BUD Hfa vMDI 1 FP DPI 3 |
| Daily ICS dose/m2 (range) | BUD equivalent 439* (108–1058) µg HC equivalent‡ 5.5* (1.3–13.2) mg |
| Duration of ICS therapy (range) | 41* (2–157) months |
| n on NS (% of total) | 122/143 (85) |
| NS | BDP 118 BUD 4 |
| Daily NS dose/m2 (range) | BUD equivalent 118* (54–468) µg HC equivalent 1.5* (0.7–5.9) mg |
| Duration of NS therapy (range) | 36* (2–136) months |
| n on OCS (% of total) | 5/143 (3) |
| Daily OCS dose/m2 (range) | HC equivalent§ 125.5* (17.5–187.3) mg |
| n on TS (% of total) | 60/143 (42) |
| TS | Fluocinolone, betamethasone, methylprednisolone aceponate, hydrocortisone |
| Duration of TS therapy (range) | 30* (0.25–356) months |
| n on steroid eye drops (% of total) | 4/143 (3) |
| Steroid eye drops | Fluoromethalone 3 Dexamethasone 1 |
*Median.
†As established by Asthma Control Questionnaire.
‡80 µg BUD is comparable to 1 mg HC in potency.
§1 mg prednisone equates to 4 mg HC in potency.
BUD, budesonide; BDP, Beclomethasone diproprionate; DPI, dry powder inhaler; FP, fluticasone proprionate; HFA, hydrofluroalkane; HC, hydrocortisone; ICS, inhaled corticosteroids; MDI, metered dose inhaler; NS, Nasal steroids; OCS, oral corticosteroids (prednisone) given for maintenance or exacerbation (ONMTPT performed while on OCS); TS, topical steroids.